Navigation Links
QuatRx Completes Enrollment of Ophena(TM)(Ospemifene Tablets) Final Pivotal Phase 3 Study in Women with Postmenopausal Vaginal Atrophy
Date:3/31/2009

tment period. All women are also being supplied with a non-hormonal vaginal lubricant to be applied as needed during the treatment period. The co-primary endpoints of the study are the change from baseline to week 12 in the percentage of parabasal cells in the vaginal maturation index, the percentage of superficial cells in the vaginal maturation index, vaginal pH, and improvements in the most bothersome moderate to severe vulvovaginal atrophy symptoms of vaginal dryness and dyspareunia.

The study is the second pivotal Phase 3 clinical trial for Ophena(TM), a novel selective estrogen receptor modulator (SERM) for the treatment of vaginal atrophy. Vaginal atrophy is a common condition in postmenopausal women characterized by progressive long-term vaginal symptoms such as dryness, irritation and sexual pain (dyspareunia). The first Phase 3 trial for Ophena(TM) met all the co-primary endpoints at the 60mg dosage, with statistically significant improvements in vaginal dryness and dyspareunia, as well as statistically significant improvement in the proportion of parabasal and superficial cells in the epithelium of vaginal walls and a decline in vaginal pH levels.

About Postmenopausal Vaginal Atrophy

Postmenopausal vaginal atrophy is a chronic and progressive condition characterized by symptoms including vaginal dryness, sexual pain (dyspareunia) and irritation. Declining estrogen levels during menopause can cause tissues of the vaginal lining to grow thinner and to lose elasticity, a condition known as vaginal atrophy. Dryness and irritation associated with reductions in vaginal secretions often cause pain or bleeding during sexual intercourse. It is estimated that 45-75 percent of postmenopausal women experience chronic symptoms of vaginal atrophy which are bothersome in over 90 percent of cases. Current prescription treatments approved for this condition all contain estrogen, administered either orally or
'/>"/>

SOURCE QuatRx Pharmaceuticals
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. QuatRx Completes Patient Enrollment in Phase 3 Study of Ophena(TM) in Women with Postmenopausal Vaginal Syndrome
2. QuatRx Pharmaceuticals Announces Positive Phase 3 Results for Study of Ophena(TM) (ospemifene) to Treat Postmenopausal Vaginal Syndrome
3. QuatRx Pharmaceuticals Announces Presentation of Further Data from Ophena(TM) (Ospemifene) Phase 3 Study for Treatment of Symptoms of Vulvovaginal Atrophy
4. Quatrx Pharmaceuticals Presents Results From Ophena(TM) (Ospemifene Tablets) Phase 3 Study Related to Treatment of Symptoms of Vulvovaginal Atrophy
5. QuatRx Initiates Second Phase 3 Study of Ophena(TM) (Ospemifene Tablets) in Women With Postmenopausal Vaginal Syndrome
6. QuatRx Pharmaceuticals Announces Additional Data From Phase 3 Study for Ophena(TM) (Ospemifene Tablets) Showing Improvements in Clinical Symptoms of Vulvovaginal Atrophy
7. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
8. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
9. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
10. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
11. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2015)... 1, 2015 The global ... basis of sectors, products & services and application. And ... with the increasing demand of advanced drugs for ... propel the growth for bioinformatics market. The implementation ... is known as bioinformatics. Decreasing cost of DNA ...
(Date:9/1/2015)... DUBLIN , Aug. 31, 2015 ... the addition of the "Introduction to Veterinary ... to their offering. This course ... a good introduction to those concerned with Veterinary ... experienced personnel who reqire a better understanding of ...
(Date:9/1/2015)... , Sept. 1, 2015  Abbott (NYSE: ABT ... a multi-center, randomized trial comparing the safety and effectiveness ... ® , Abbott,s market-leading, permanent drug eluting stent. ... Japan and enrolled 400 people with ... disease. The results will be featured at a late-breaking ...
Breaking Medicine Technology:Global Bioinformatics Market Valued at Over $1.3 Billion in 2013 and is Expected to Grow at CAGR of 20.3% From 2014 to 2020: Hexa Research 2Global Bioinformatics Market Valued at Over $1.3 Billion in 2013 and is Expected to Grow at CAGR of 20.3% From 2014 to 2020: Hexa Research 3Global Bioinformatics Market Valued at Over $1.3 Billion in 2013 and is Expected to Grow at CAGR of 20.3% From 2014 to 2020: Hexa Research 4Introduction to Veterinary Pharmacovigilance Seminar (London, UK - September 23-24) 2Abbott Announces Positive Results of Its Naturally Dissolving Stent from ABSORB Japan Study 2Abbott Announces Positive Results of Its Naturally Dissolving Stent from ABSORB Japan Study 3Abbott Announces Positive Results of Its Naturally Dissolving Stent from ABSORB Japan Study 4
... has released an updated AutoLabel solution with enhanced customized ... virtually 100% of medications have a scan-ready bar code ... AutoLabel is a complete barcoding solution that provides color-coded ... improve patient safety at the bedside. New features include ...
... ("CTI") (NASDAQ and MTA: CTIC) announced that final results ... relapsed or refractory acute myeloid leukemia ("AML") was selected ... of Hematology ("ASH") Annual Meeting, which will be held ... Jorge Cortes, M.D., of The University of ...
Cached Medicine Technology:Talyst Updates Its AutoLabel® Solution 2Tosedostat OPAL Study Final Results Selected for Oral Presentation at the 2011 American Society of Hematology (ASH) Annual Meeting 2Tosedostat OPAL Study Final Results Selected for Oral Presentation at the 2011 American Society of Hematology (ASH) Annual Meeting 3Tosedostat OPAL Study Final Results Selected for Oral Presentation at the 2011 American Society of Hematology (ASH) Annual Meeting 4
(Date:9/1/2015)... ... , ... From Aug. 17-21, Calvary Hospital hosted the 18th consecutive session of ... has taken place at Kingsborough Community College in Brooklyn in each of the past ... Calvary, and two junior counselors who were campers themselves just a few years ago. ...
(Date:9/1/2015)... ... September 01, 2015 , ... Consumers overwhelmingly prefer ... for Dermatologic Surgery, according to a new survey that also offers insight on ... Dermatologic Procedures – which reflects views on cosmetic medical treatments and ratings for ...
(Date:9/1/2015)... , ... September 01, 2015 , ... ... is now offering the MonaLisa Touch® , an innovative vaginal health laser ... Touch® is a new hormone-free treatment for atrophic vaginitis, a condition that causes ...
(Date:9/1/2015)... ... 01, 2015 , ... With former IBMers among its founding members, Inmar has ... more than 35 years ago. A pilot program begun by the company in 2014 ... just those intent on pursuing careers in these fields. The program is now open ...
(Date:9/1/2015)... ... September 01, 2015 , ... ... D.O., has joined its medical management team as an Associate Medical Director. ... sizes and types in the U.S. and abroad. , Dr. Nelson has ...
Breaking Medicine News(10 mins):Health News:Calvary Hospital Hosts 18th Annual Bereavement Camp 2Health News:Calvary Hospital Hosts 18th Annual Bereavement Camp 3Health News:Survey: Consumers Prefer ASDS Members 2Health News:Survey: Consumers Prefer ASDS Members 3Health News:Houston's Plaza OB/GYN Now Offering the MonaLisa Touch® 2Health News:Houston's Plaza OB/GYN Now Offering the MonaLisa Touch® 3Health News:Inmar Announces Program to Fuel Student Passion for STEM – with an Unconventional Twist 2Health News:Dr. Brent Nelson Joins WorkCare, Inc., as Associate Medical Director 2Health News:Dr. Brent Nelson Joins WorkCare, Inc., as Associate Medical Director 3
... at Jefferson Medical College have shown that capsule endoscopy ... bowel Crohns disease in children. The technology has been ... than five years to diagnose unexplained abdominal bleeding in ... not much bigger than a vitamin pill and can ...
... schools and colleges staged protest here on Friday against Government's ... ,Moves to bring sex out of the closet have kicked ... will reduce number of HIV cases, and critics, who fear ... and posters, men and women, with support from a political ...
... continues to grow over school mandates for Gardasil a ... for girls ages 11 to 12 that is designed ... linked to cervical cancer and genital warts the majority ... issue: They do not want the vaccine to be mandated. ...
... heat can decrease sperm count, and retard the surviving sperm. ... Cambridgeshire have suggested that soaking up the sun in tight trunks ... ,Many couples believe that a foreign break develops their probability ... ,However, sperm takes eight weeks to fully grow in the ...
... the parents of an estimated one in 20,000 newborns are ... dystrophy (CDM1), a progressive and crippling genetic disorder. Although ... prenatal tests are available, many children are not diagnosed until ... that they have type 1 myotonic dystrophy (DM1) a ...
... tooth paste and now fish. There just seems to be no ... two days ago the US put on hold all imports of ... whether it contains diethylene glycol, a chemical commonly used in antifreeze ... packages of fish imported from China into the United States and ...
Cached Medicine News:Health News:Most Parents in U.S. Not in Favor of HPV Vaccine Mandates 2Health News:Most Parents in U.S. Not in Favor of HPV Vaccine Mandates 3Health News:Researcher Studying Disease That Cripples Newborns 2Health News:US Consumers Warned Against Toxic Chinese Fish 2
... ergonomic chairs with concave seats ... support • Select options like ... and glides. • BTT/1P chairs ... environments: industry, education, laboratory, clean ...
... with concave seats and standard-sized ... Select options like seats, backrests, ... • BTT/1P chairs are recommended ... education, laboratory, clean room, static ...
... chairs with concave seats and large ... options like seats, backrests, armrests, and ... BE Series for top performance in ... education, laboratory, clean room, static control, ...
... ergonomic chairs with concave seats and ... Select options like seats, backrests, armrests, ... the BE Series for top performance ... industry, education, laboratory, clean room, static ...
Medicine Products: